Upcoming Financial Highlights for NEXGEL in Second Quarter

NEXGEL Announces Financial Results Reporting Date
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), recognized for their innovative hydrogel products, is gearing up to report significant financial results for the second quarter of the fiscal year. This upcoming event is set to occur after the market closes on August 12, 2025. NEXGEL continues its commitment to transparency and stakeholder engagement by hosting a conference call on the same day at 4:30 P.M. ET.
Details of the Conference Call
The financial results conference call provides an opportunity for stakeholders to gain insights into NEXGEL’s performance and future outlook. Here are the essential details:
Date and Time
Date: August 12, 2025
Time: 4:30 P.M. ET
Dial-in Information
For those wishing to participate, please use the following numbers: 1-800-274-8461 for U.S. participants or +1-203-518-9814 for international calls. Don’t miss this chance to hear directly from the management about the company’s achievements and future direction!
Replay Information
For individuals unable to attend the call live, a replay option will be available until August 26, 2025. Participants can access the replay by dialing +1-844-512-2921 for U.S. toll-free calls or +1-412-317-6671 for international listeners. To access the replay of the call, please use the code: 11159686. Additionally, an archived version of the webcast will remain available for 90 days, ensuring that all interested parties can catch up on this vital information.
About NEXGEL, INC.
NEXGEL stands out as a pioneering manufacturer of high-water-content hydrogel products tailored for healthcare, beauty, and over-the-counter (OTC) applications. Based in Langhorne, Pa., the company has a rich history of developing and producing electron-beam, cross-linked hydrogels for over twenty years. Their diverse range of brands includes industry favorites such as Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. With strategic relationships established in contract manufacturing with leading consumer healthcare brands, NEXGEL continues to drive innovation and growth in the sector.
Investor Relations Contact
For further information, please reach out to:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Email: Nexgel@KCSA.com
Frequently Asked Questions
What financial results will NEXGEL report?
NEXGEL will report its second-quarter financial results for 2025, providing insights into their performance and strategy.
When is the conference call taking place?
The conference call will occur on August 12, 2025, at 4:30 P.M. ET.
How can I join the conference call?
You can join the call by dialling 1-800-274-8461 (U.S. Toll Free) or +1-203-518-9814 (International).
Is a replay available for the conference call?
Yes, a replay will be available until August 26, 2025.
What products does NEXGEL offer?
NEXGEL provides ultra-gentle, high-water-content hydrogels for various applications in healthcare and consumer markets.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.